Business context and reporting period
Edgewise Therapeutics, Inc. filed this Form 10-K for the fiscal year ended December 31, 2023. The clinical-stage biopharmaceutical company has no approved products and focuses on medicines for severe muscle diseases. Its lead candidate, EDG-5506, is in Phase 2 studies for muscular dystrophies and related conditions; EDG-7500 entered Phase 1 in 2023 for hypertrophic cardiomyopathy (HCM). EDG-003 remains in discovery/preclinical development. The company retains global development and commercialization rights to its programs.
Financial and operating metrics
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $90.9 million | $54.0 million |
| General and administrative expense | $23.5 million | $17.6 million |
| Total operating expense | $114.4 million | $71.7 million |
| Interest income | $14.2 million | $4.0 million |
| Net loss | $100.2 million | $67.6 million |
| Net loss per share, basic and diluted | $1.57 | $1.26 |
| Net cash used in operating activities | $91.9 million | $52.6 million |
At December 31, 2023, cash and cash equivalents were $86.1 million and marketable securities were $232.3 million, totaling $318.4 million. Total assets were $340.0 million, total liabilities $21.2 million, and stockholders’ equity $318.8 million. The filing reports no debt borrowings; operating lease liabilities totaled $5.4 million. No revenue means revenue margins are not meaningful. Management expected year-end cash, cash equivalents and marketable securities to fund the operating plan for at least 12 months from issuance of the financial statements.
Material changes versus the prior comparable period
- Net loss increased $32.5 million year over year, while operating expenses rose $42.7 million. R&D increased $36.9 million, primarily with greater EDG-5506 trial/manufacturing activity, EDG-7500 entering Phase 1, and higher personnel costs.
- Interest income increased $10.2 million, reflecting higher investment balances and interest rates; this partially offset higher operating costs.
- Operating cash use increased $39.3 million. Financing provided $53.2 million in 2023, principally from $52.6 million net ATM proceeds, compared with $129.6 million in 2022, largely from the September 2022 offering.
- Common shares outstanding rose to 70.5 million at year-end from 63.3 million a year earlier, reflecting equity issuance and employee equity activity.
Outlook, management commentary and key risks
- EDG-5506: The filing reports that ARCH 12-month open-label data showed average reductions in CK of 37% and TNNI2 of 79%; NSAA scores improved by 0.4 points on average, versus a cited natural-history decline of 1.2 points. These small, open-label findings are not confirmatory evidence of efficacy. CANYON enrollment was complete; the potentially registrational GRAND CANYON cohort planned to enroll about 120 adults with Becker over 18 months. DUNE was fully enrolled. Phase 2 Duchenne studies LYNX and FOX were underway.
- EDG-7500: A Phase 1 trial began in September 2023. Management planned Phase 2 studies in obstructive HCM in the first half of 2024 and expected Phase 1 data in the third quarter of 2024. These are plans stated in the filing, not reported outcomes.
- Financing after year-end: The company suspended its ATM prospectus in January 2024 after total ATM sales of 7.56 million shares for $59.9 million gross proceeds. A January 2024 registered direct offering generated $240.0 million gross proceeds from 21.8 million shares. This is post-period financing and increases the share count.
- Risks and contingencies: The company has no product revenue, has incurred recurring losses, and will require substantial additional capital to advance candidates. Clinical outcomes, regulatory approval, patient enrollment, competition, reimbursement, intellectual-property protection, and reliance on third-party CROs and manufacturers are significant uncertainties. Manufacturing relies on third parties without long-term supply arrangements or redundant supply. No material legal proceedings were reported.
- Listing and controls: Nasdaq notified the company in July 2023 that it was not compliant with audit-committee composition requirements; the filing states a deadline of June 19, 2024 (or the next annual meeting, if earlier) to regain compliance. Management reported effective disclosure controls and internal control over financial reporting at year-end; the auditor did not provide an internal-control attestation because of the company’s emerging-growth-company exemption.
- The FDA granted EDG-5506 Orphan Drug and Rare Pediatric Disease designations for specified indications in November 2023 and Fast Track designation for Duchenne in February 2024. Designations do not assure approval or commercial success.
The filing provides no formal revenue or earnings guidance; it describes development plans and estimates of cash runway, both subject to clinical, spending and financing uncertainties.
Most important facts for investors to verify
- Enrollment, trial design, endpoint results and safety for GRAND CANYON and the ongoing LYNX, FOX and other EDG-5506 studies; distinguish interim or open-label biomarker findings from controlled functional efficacy.
- EDG-7500 Phase 1 results and whether planned Phase 2 HCM studies commenced on the stated timeline.
- Post-offering cash balance, quarterly cash burn and management’s updated runway estimate after the January 2024 financing.
- Nasdaq audit-committee compliance status and any subsequent listing notices.
- Manufacturing capacity and supply redundancy, as well as share dilution from recent and future equity financing.